Rankings
▼
Calendar
SNDX (Syndax Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
SNDX
Syndax Pharmaceuticals, Inc.
Mkt Cap
$2B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$172M
Net Income (TTM)
-$285M
EPS (TTM)
-$3.30
Free Cash Flow (TTM)
-$323M
Gross Margin
96.0%
Op. Margin
-158.4%
Net Margin
-165.6%
FCF Margin
-187.5%
P/S Ratio (TTM)
12.5x
P/E Ratio (TTM)
—
YoY Rev Growth
+627.8%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$0
$0
-$46M
Q2 23
$0
$0
-$50M
Q3 23
$0
$0
-$56M
Q4 23
$0
$0
-$78M
Q1 24
$0
$0
-$80M
Q2 24
$4M
$4M
-$74M
Q3 24
$13M
$13M
-$90M
Q4 24
$8M
$8M
-$96M
Q1 25
$20M
$19M
-$84M
Q2 25
$38M
$37M
-$69M
Q3 25
$46M
$39M
-$57M
Q4 25
$68M
$70M
-$63M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
—
—
Q2 23
—
—
Q3 23
—
—
Q4 23
—
—
Q1 24
—
—
Q2 24
615.6x
—
Q3 24
134.7x
—
Q4 24
91.0x
—
Q1 25
49.3x
—
Q2 25
27.6x
—
Q3 25
19.3x
—
Q4 25
12.5x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$39M
-$39M
Q2 23
-$35M
-$35M
Q3 23
-$45M
-$45M
Q4 23
-$41M
-$41M
Q1 24
-$84M
-$84M
Q2 24
-$72M
-$72M
Q3 24
-$62M
-$62M
Q4 24
-$57M
-$57M
Q1 25
-$95M
-$95M
Q2 25
-$88M
-$88M
Q3 25
-$71M
-$71M
Q4 25
-$69M
-$70M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$0
Q2 23
$0
Q3 23
$0
Q4 23
$0
Q1 24
$0
Q2 24
$0
Q3 24
$0
Q4 24
$0
Q1 25
$0
Q2 25
$0
Q3 25
$131K
Q4 25
$56K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
—
+24.8%
Q2 23
—
+31.7%
Q3 23
—
+60.4%
Q4 23
—
+85.3%
Q1 24
—
+72.8%
Q2 24
—
+56.4%
Q3 24
—
+81.1%
Q4 24
—
+33.6%
Q1 25
—
+30.5%
Q2 25
+984.5%
+38.1%
Q3 25
+267.0%
+1.2%
Q4 25
+791.7%
+25.9%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$6M
—
Q2 23
$8M
—
Q3 23
$8M
—
Q4 23
$8M
—
Q1 24
$9M
—
Q2 24
$10M
282.7%
Q3 24
$12M
95.5%
Q4 24
$12M
160.1%
Q1 25
$10M
51.8%
Q2 25
$14M
36.3%
Q3 25
$12M
26.3%
Q4 25
$11M
16.4%
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q1 23
$34M
$12M
—
Q2 23
$35M
$15M
—
Q3 23
$39M
$17M
—
Q4 23
$55M
—
$23M
Q1 24
$56M
$23M
—
Q2 24
$49M
$29M
—
Q3 24
$71M
$31M
—
Q4 24
$66M
$38M
—
Q1 25
$62M
$41M
—
Q2 25
$62M
$44M
—
Q3 25
$56M
—
$45M
Q4 25
$79M
$50M
—
marketcaparena.com
Revenue Segments
Collaboration revenue
Product
Quarter
Collaboration revenue
Product
Q2 25
$9M
$29M
Q3 25
$14M
$32M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$58M
$375M
$432M
Q2 23
$97M
$309M
$406M
Q3 23
$95M
$269M
$364M
Q4 23
$295M
$282M
$578M
Q1 24
$115M
$320M
$435M
Q2 24
$105M
$320M
$425M
Q3 24
$133M
$257M
$390M
Q4 24
$154M
$429M
$583M
Q1 25
$154M
$362M
$516M
Q2 25
$109M
$360M
$469M
Q3 25
$117M
$337M
$454M
Q4 25
$135M
$259M
$394M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
69M
+9.9%
Q2 23
70M
+0.3%
Q3 23
70M
+0.3%
Q4 23
73M
+3.8%
Q1 24
85M
+17.5%
Q2 24
85M
+0.1%
Q3 24
85M
+0.2%
Q4 24
86M
+0.4%
Q1 25
86M
-0.2%
Q2 25
86M
+0.8%
Q3 25
87M
+0.3%
Q4 25
87M
+0.0%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
$38K
32
FY 17
$48K
44
FY 18
$40K
38
FY 19
$43K
35
FY 20
$35K
43
FY 21
$2M
59
FY 22
$0
107
FY 23
$0
184
FY 24
$88K
270
FY 25
$613
281K
marketcaparena.com